The latest price target for Corvus Pharma (NASDAQ:CRVS) was reported by Ladenburg Thalmann on September 16, 2024. The analyst firm set a price target for $21.00 expecting CRVS to rise to within 12 months (a possible 245.39% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Corvus Pharma (NASDAQ:CRVS) was provided by Ladenburg Thalmann, and Corvus Pharma maintained their buy rating.

There is no last upgrade for Corvus Pharma

There is no last downgrade for Corvus Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corvus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corvus Pharma was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Corvus Pharma (CRVS) rating was a maintained with a price target of $12.00 to $21.00. The current price Corvus Pharma (CRVS) is trading at is $6.08, which is out of the analyst’s predicted range.